Profound Medical Corp (PROF)

$4.74 -0.02 (-0.52%)
Market Cap 150.27M
Revenue (ttm) 10.68M
Net Income (ttm) -27.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -260.49%
Debt to Equity Ratio 0.08
Volume 18,716
Avg Vol 80,806
Day's Range N/A - N/A
Shares Out 30.05M
Stochastic %K 55%
Beta 0.68
Analysts Strong Sell
Price Target $13.81

Latest News on PROF

Profound Medical AUA 2025 Investor Event Agenda

Apr 15, 2025, 7:45 AM EDT - 13 days ago

Profound Medical AUA 2025 Investor Event Agenda

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 8, 2025, 10:00 AM EDT - 20 days ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Apr 8, 2025, 9:32 AM EDT - 20 days ago

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Apr 7, 2025, 10:00 AM EDT - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Apr 6, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Apr 4, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Apr 3, 2025, 10:00 AM EDT - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 26 days ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Apr 1, 2025, 10:00 AM EDT - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Mar 31, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Mar 28, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Mar 27, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Mar 26, 2025, 9:59 PM EDT - 4 weeks ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Mar 26, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Mar 25, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Mar 24, 2025, 1:00 PM EDT - 5 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Mar 6, 2025, 8:35 PM EST - 7 weeks ago

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Feb 13, 2025, 5:00 PM EST - 2 months ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 8, 2025, 7:30 AM EST - 3 months ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:15 AM EST - 4 months ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Dec 10, 2024, 9:55 AM EST - 4 months ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Dec 6, 2024, 9:04 AM EST - 5 months ago

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Proposed Public Offering of Common Shares

Dec 5, 2024, 4:48 PM EST - 5 months ago

Profound Medical Announces Proposed Public Offering of Common Shares

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Dec 2, 2024, 7:30 AM EST - 5 months ago

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Nov 26, 2024, 7:45 AM EST - 5 months ago

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Nov 10, 2024, 8:50 AM EST - 6 months ago

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Nov 4, 2024, 6:55 AM EST - 6 months ago

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Oct 17, 2024, 4:30 PM EDT - 6 months ago

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Oct 16, 2024, 4:15 PM EDT - 6 months ago

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

Sep 4, 2024, 4:30 PM EDT - 8 months ago

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:11 PM EDT - 9 months ago

Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Jul 18, 2024, 4:30 PM EDT - 10 months ago

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Jul 11, 2024, 7:00 AM EDT - 10 months ago

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

Profound Medical Annual General Meeting of Shareholders Voting Results

May 15, 2024, 5:00 PM EDT - 1 year ago

Profound Medical Annual General Meeting of Shareholders Voting Results

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan

May 14, 2024, 7:30 AM EDT - 1 year ago

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan

Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:47 PM EDT - 1 year ago

Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript

Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

May 6, 2024, 4:15 PM EDT - 1 year ago

Growing Body of Clinical Evidence Points to the Potential of Profound Medical's TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

Apr 22, 2024, 4:15 PM EDT - 1 year ago

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 9, 2024, 7:45 AM EDT - 1 year ago

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 11:35 PM EST - 1 year ago

Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 4:05 PM EST - 1 year ago

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

Mar 4, 2024, 4:30 PM EST - 1 year ago

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Feb 27, 2024, 7:45 AM EST - 1 year ago

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

Feb 15, 2024, 4:30 PM EST - 1 year ago

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

Profound Medical Announces Non-Brokered Private Placement

Jan 16, 2024, 4:30 PM EST - 1 year ago

Profound Medical Announces Non-Brokered Private Placement

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues

Jan 3, 2024, 4:15 PM EST - 1 year ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues